We developed a patient specific cancer vaccine comprised of immune stimulating cells fused with patient derived myeloma cells. We have shown that vaccination with fusion cells stimulates the immune system to target and eliminate myeloma cells. We will examine whether vaccination prior to and following stem cell transplantation more effectively stimulates anti-tumor immune responses and eliminates the small number of chemotherapy resistant myeloma cells that commonly survive after transplant. We will collect immune cells from patients who been vaccinated and examine a strategy to expand anti-tumor cells in the laboratory to further enhance the effectiveness of the vaccine.